Cite
MLA Citation
Jeffrey A Cohen et al.. “Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.” Lancet neurology, vol. 15, no. 4, n.d., pp. 373–381. http://access.bl.uk/ark:/81055/vdc_100030952457.0x00000d